Zai Lab
ZLAB | NASDAQ
$23.47
-$1.13 (-4.59%)
At close: Nov 16, 2026, 4:00 PM ET
$23.47
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Zai Lab Company Profile
Company profile explainedCompany Profile
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Key Executives
| Name | Position |
|---|---|
| Ying Du | Founder, Chairperson & Chief Executive Officer |
| Frazor Titus Edmondson | Chief Legal Officer & Corporate Secretary |
| James Yan DABT | Chief Operating Officer of Global R&D |
| Yajing Chen | Chief Financial Officer |
| Christine Chiou | Senior Vice President & Head of Investor Relations |
| Rafael G. Amado | President and Head of Global Research & Development |
| Shan He | Senior Vice President & Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 06, 2026 | 4 | Filing |
| Jul 06, 2026 | 4 | Filing |
Zai Lab
| Country | China |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,784 |
| CEO | Ying Du |
Contact Details
Jinchuang Plaza Shanghai,
SH 201210 China
Stock Details
| Ticker Symbol | ZLAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704292 |
| CUSIP Number | 98887Q104 |
| ISIN Number | US98887Q1040 |
| SIC Code | 2834 |
Recent News
- 15 hours ago / seekingalpha.comZai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
- 3 days ago / businesswire.comZai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
- 3 days ago / businesswire.comZai Lab Announces Participation in Investor Conferences in November 2026
- 3 days ago / benzinga.comZai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
- 3 days ago / seekingalpha.comZai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
- 3 days ago / businesswire.comZai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
- 6 days ago / zacks.comWall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
- 10 days ago / marketbeat.comZai Lab Q3 Earnings Call Highlights
- 11 days ago / seekingalpha.comZai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comZai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Add to Watchlist
Select watchlists to add or remove ZLAB